TEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B

Teva Pharmaceutical Industries Limited TEVA reported second-quarter 2022 adjusted earnings of 68 cents per share, which beat the Zacks Consensus Estimate of 57 cents. Earnings rose 15.3% year over year.